Data investigation

The Peptide Menu: What Has Human Trials and What Does Not

In August 2026, 152 of the 560 sellers we tracked ran a peptide menu. We counted the human randomized trials behind each one. BPC-157: 226 papers, zero. The peptides with real evidence are the ones that became approved drugs.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
8 min read·1 citation

Part of Peptides: what the evidence shows

A large share of GLP-1 sellers now run a peptide menu alongside the injections. When we counted on August 19, 2026, 152 of the 560 in our register had a structured one. The menus look alike, and they mix things with decades of human trials behind them and things with none at all. This is that menu, sorted by what has been tested in people.

The table

Every row was counted the same way on the same day: a plain PubMed search for the peptide, then the same search restricted to randomized controlled trials in humans. Seller counts come from the structured product menus in our own register.

Peptides on seller menus, against the human trial record. PubMed counts pulled August 19, 2026. A count of papers is a crude measure and not a judgment of quality.
PeptideSellers offering itIndexed papersHuman RCTs
Sermorelin11333119
GHK-Cu (copper peptide)321782
PT-141 (bremelanotide)2910914
BPC-157152260
Ipamorelin12542
Tesamorelin1112126
CJC-129510331
MOTS-c52504, none giving MOTS-c
KPV3530
Epitalon11320
NAD+ is left out of the table on purpose, because its row would mislead. It was the most-offered item of all in the same August 19 count (153 sellers), but the trials are of oral precursors while what is sold is an injection, and a 2026 systematic review found no outcomes trials of the injected form at all. It gets its own piece: NAD+ injections and what the evidence shows. The oral NMN and NR trials on aging are covered in NAD+ and longevity.

The pattern in that table

Read the last column against the first. The peptides carrying real human trial evidence are, almost without exception, the ones that became approved drugs. If the term is new to you, what is peptide therapy? sorts the menu into approved drugs, compounded peptides and research-use-only vials.

  • Tesamorelin has 26 human randomized trials because it was developed into an approved product for a specific condition, excess abdominal fat in people with HIV-associated lipodystrophy.
  • Bremelanotide has 14 for the same reason, in a completely different area: it was approved for hypoactive sexual desire disorder in premenopausal women.
  • Sermorelin has 19, from its history as a growth-hormone agent rather than from anything to do with weight.
  • MOTS-c shows the limit of this count. Its four records are exercise, heat and metformin studies that measured the body’s own MOTS-c. None gave MOTS-c to anyone.
  • BPC-157 and epitalon have zero, across 226 and 132 indexed papers respectively. The research is real and mostly preclinical, in cells and animals. The few epitalon courses given to people are set out in epitalon dosage and courses. Thymosin alpha 1 is the instructive exception: licensed abroad, mainly for hepatitis B, it has human trials, though not for the uses it is sold for here.
Evidence attaches to a drug for an indication, not to a molecule in general.

That sentence is the one worth taking away, because it is where the marketing goes wrong even when the citations are genuine. Tesamorelin’s 26 trials are excellent evidence for what tesamorelin does in HIV-associated lipodystrophy. They are not evidence about a person without HIV buying it for belly fat, and the trials cannot be borrowed across. We look at that specific gap in tesamorelin for weight loss.

What a zero means, and what it does not

Zero human randomized trials does not mean a substance was tested and failed. It means the test has not been run, which is where LL-37 stands despite thousands of papers. AOD-9604 is the weight-loss peptide that was tested in people and failed, as peptides for weight loss sets out. The same is true of non-peptides sold on these menus, such as 5-amino-1MQ, which has mouse data and no published human study. Tesofensine is the opposite case: real human trials, and still no approval. Those are different situations, and we keep them apart. The register has no interest in dismissing something that might turn out to work.

But it does settle one thing. Where there are no human trials, nobody knows the dose, the duration or what happens over years, and that includes the clinic writing the prescription. For BPC-157, the few doses ever given to people are set out in BPC-157 dosage in the studies. Any confident claim made to you about benefit is coming from somewhere other than a trial in people. What a lab panel can and cannot show about these products is covered in peptide blood work. For BPC-157 specifically there is also a regulatory dimension, covered in what the FDA actually said about BPC-157, and a short human safety record, covered in BPC-157 side effects.

The counts above are a crude instrument and should be treated as one. A count of indexed papers says nothing about whether the trials were good, how large they were, or whether they measured anything a patient would notice. It is a rough map of where human evidence exists at all. That makes it useful for spotting a zero and useless for ranking a 19 against a 26.

Questions worth asking about anything on the menu

  1. Which condition was it tested in, and am I that person? This single question disposes of most peptide marketing.
  2. Was it tested in people, or in cells and animals? Preclinical work is real science and it is not a reason to buy something today.
  3. What dose, for how long, and from what? Where there are no human trials, these numbers came from somewhere other than evidence.
  4. Can it lawfully be compounded at all? Some cannot (see what cannot legally be compounded).
  5. Who made it, and will they tell me? Covered in what makes a telehealth prescription legitimate.

Frequently Asked Questions

Not randomized ones. A search on August 19, 2026 returned 226 indexed papers and zero human randomized controlled trials. The research that exists is largely preclinical, in cells and animals. That is an absence of testing rather than a failed test, but it means the dose, duration and long-term picture are unknown to everyone, including whoever is selling it.
Overwhelmingly the ones that became approved drugs for a specific condition: tesamorelin (26 human randomized trials), bremelanotide or PT-141 (14), and sermorelin (19). Among those sold purely as wellness products, BPC-157, epitalon and KPV sit at zero and CJC-1295 at one. MOTS-c shows four, but those studies measured the body's own MOTS-c; none gave it as a treatment.
It is proven for the condition it was studied and approved in: excess abdominal fat in people with HIV-associated lipodystrophy. Evidence attaches to a drug for an indication, not to a molecule in general, so those trials do not carry across to someone without HIV buying it for general fat loss.
As a rough map only. It shows where human evidence exists at all, which is enough to spot a zero, but it says nothing about trial quality, size, or whether the endpoints mattered. It is also sensitive to how the search is built. An earlier version of this count using a title-and-abstract restriction reported sermorelin at zero when the correct figure is 19, because it missed records indexed under a subject heading.
Because the same visit and the same shipping already exist, so an added product is close to pure margin. When we counted on August 19, 2026, 152 of the 560 sellers in our register ran a structured peptide menu alongside their GLP-1 offering.

References

  1. 1.National Library of Medicine. PubMed — record counts by peptide and by publication type, retrieved August 19, 2026; every row queried identically (plain term, then the same term restricted to randomized controlled trial[pt] AND humans[mh]) PubMed. 2026. https://pubmed.ncbi.nlm.nih.gov/

NAD+ Injections: What the Evidence Shows

A 2026 systematic review screened 113 studies and found no outcomes trials of injected NAD+ for anti-aging or wellness. With sermorelin, it is one of the two most common add-ons in our register: 142 of 560 sellers offered NAD+ and 147 offered sermorelin at the August 2026 count.

7 min read

BPC-157 FDA Status: What the Agency Put on the Record

Not approved, and not on the list of substances a 503A compounding pharmacy may use. FDA recorded specific concerns: immunogenicity, peptide impurities, and “no, or only limited, safety-related information”.

8 min read

Tesamorelin for Weight Loss? Read Its Own Label

Tesamorelin is FDA-approved, for reducing abdominal fat in HIV-associated lipodystrophy. Its label carries six words that matter: “Not indicated for weight loss management.”

6 min read

CJC-1295 and Ipamorelin: What FDA Recorded

Sold as a stack for fat loss. FDA identified serious adverse events with CJC-1295 (increased heart rate and systemic vasodilatory reaction), and neither peptide has a weight-loss trial.

7 min read

Retatrutide: What the Evidence Actually Shows

TRIUMPH-1 is now peer-reviewed: 25.0% at 80 weeks counting everyone randomized, against 28.3% in Lilly's release for the same trial. The drug is approved nowhere, and Lilly has not yet filed.

8 min read

The Add-On Menu

At our August 2026 count, 152 of 560 sellers ran a peptide menu. Ranked by how often items appear, it is almost exactly the inverse of a ranking by evidence, and the reason is commercial rather than clinical.

5 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.3

Embody

A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

6.4

Bodybuilding Health+

Seeing what it charges before you answer any medical questions

9.0

YourEra

Semaglutide at $99/month, well below the typical price

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →